INS and early-onset autosomal dominant Alzheimer disease: The intranasal administration of an insulin aqueous solution has also been widely studied in up to Phase 2/3 clinical trials, as a therapy for Alzheimer’s disease, mild cognitive impairment, diabetes, insulin resistance, and Parkinson’s disease, among other conditions.